

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

Ltd.

OM nucleic - nucleic search, using SW model

Run on: September 17, 2003, 16:20:15 ; Search time 310.324 Seconds
(without alignments)

Title: US-10-026-106E-7
13909.353 Million cell updates/88CC

Scoring table: IDENTITY NUC
Perfect score: 1599
Sequence: 1 aaggccatggcgggccga.....acatccaccgaatctgtatg 1595

בנטהן. IDENTI-NOG Gapop 10.0 , Gapext 1.0

Total number of hits satisfying chosen parameters: 4332/50 seqs, 1349/1931 residues

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0% Maximum Match 100%

Database: 2009
Listing first 45 summaries
N: Generate 107-103 ^

Salavabe :
N_Geneseq 19JUN03;
1: /SIDS1/gcdata/geneseq/
2: /SIDS1/gcdata/geneseq/

```
3: /SIDS1/gcadata/geneseq  
4: /SIDS1/gcadata/geneseq/  
5: /SIDS1/gcadata/geneseq/
```

```
6: /SIDS1/gcadata/geneseq/  
7: /SIDS1/gcadata/geneseq/  
8: /SIDS1/gcadata/geneseq/
```

9: /SIDS1/gcdata/geneseq/
9: /SIDS1/gcdata/geneseq/
10: /SIDS1/gcdata/geneseq/
11: /SIDS1/gcdata/geneseq/

```
11: /SIDS1/gcadata/geneseq
12: /SIDS1/gcadata/geneseq
13: /SIDS1/gcadata/geneseq
```

```
14: /Sbs1/gcdata/geneSeq  
15: /Sids1/gcdata/geneSeq  
16: /Sids1/gcdata/geneSeq
```

```
17: /SIDS1/gcgdata/geneseq  
18: /SIDS1/gcgdata/geneseq  
19: /SIDS1/gcgdata/geneseq
```

```
20: /SIDS1/gcdata/geneseq
21: /SIDS1/gcdata/geneseq
22: /SIDS1/gcdata/geneseq
```

```
22: /SIDS1/gcguata/geneSeq  
23: /SIDS1/gcadata/geneSeq  
24: /SIDS1/gcadata/geneSeq
```

pred. No. is the number of results produced.

Score greater than or equal to the score and is derived by analysis of the tot

SUMMARY

No.	Score	Match	Length	DB	ID
1	1540	4	66	0	1540

1	1549.4	96.9	1563	24	ABQ73078
2	1549.4	96.9	1563	25	AAD50487
3	1354.2	84.7	1476	24	ABQ73068

4	1354.2	64.7	1476	25	AAD50485
5	1086.8	68.0	1560	24	ABQ73085
6	916.2	57.3	1473	24	ABQ73069

SUMMARIES

score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

ALIGNMENT

Copyright (c) 1993 - 2003 Compugen Ltd.

GenCore version 5.1.6

Run on: September 17, 2003, 16:20:15 ; Search time 310.324 Seconds (without alignments)

OM nucleic - nucleic search, using sw model

Title: US-10-026-106B-7

Perfect score: 1599

Sequence: 1 aaggccatggggggccga.....acatccacccgaaatctatg 1599

13909.353 Million cell updates/sec

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 2525756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N_Geneset_iijun03:*

1: /SIBSI/ gegdata/geneseq/geneseq-emb1/NA1980.DAT:*

2: /SIBSI/ gegdata/geneseq/geneseq-emb1/NA1981.DAT:*

3: /SIBSI/ gegdata/geneseq/geneseq-emb1/NA1982.DAT:*

4: /SIBSI/ gegdata/geneseq/geneseq-emb1/NA1983.DAT:*

5: /SIBSI/ gegdata/geneseq/geneseq-emb1/NA1984.DAT:*

6: /SIBSI/ gegdata/geneseq/geneseq-emb1/NA1985.DAT:*

7: /SIBSI/ gegdata/geneseq/geneseq-emb1/NA1986.DAT:*

8: /SIBSI/ gegdata/geneseq/geneseq-emb1/NA1987.DAT:*

9: /SIBSI/ gegdata/geneseq/geneseq-emb1/NA1988.DAT:*

10: /SIBSI/ gegdata/geneseq/geneseq-emb1/NA1989.DAT:*

11: 498 31.1 674 25 ADD50488 Human ZcytC19 tru

12: 498 31.1 704 24 ADD3324 Human (DNAX) integr

13: 351.2 32.0 633 24 ABQ73086 Human zcytC19 deg

14: 335.4 21.0 374 22 ARF6460 Novel human Polynu

15: 165 10.3 392 22 ARF65622 Novel human polynu

16: 163.4 10.2 392 22 ARF65722 Novel human polynu

17: 128 8.0 634 22 ARH65722 Human colon cancer

18: 53.4 3.3 347 22 ARK55707 Human immune/Hema

19: 44.4 2.8 1458 23 ARK66222 Human immune/Hema

20: 44.4 2.8 3112 24 ABS7526 DNA encoding novel

21: 44.4 2.8 3115 22 ARB08672 DNA encoding novel

22: 44.4 2.8 3115 22 ARH93569 Human membrane-Typ

23: 44.4 2.8 3142 22 ARF2099 Human protein enco

24: 44.4 2.8 3147 20 AAX7815 Human membrane-Typ

25: 44.4 2.8 3147 22 RAD1313 Human membrane-Typ

26: 44.4 2.8 3147 22 RAD1315 Human membrane-Typ

27: 44.4 2.8 3147 22 AAH23601 Human TAG-15 codi

28: 44.4 2.8 3147 22 AAH23609 Human TAG-15 antit

29: 44.4 2.8 3147 24 ARL53444 Type II transmembr

30: 44.4 2.8 3147 24 AAL53445 Type II transmembr

31: 44.4 2.8 3147 25 ABZ8500 Transmembrane ser1

32: 44.4 2.8 3147 25 ABZ8501 Transmembrane ser1

33: 44.4 2.8 3147 25 ABZ22450 Human membrane-Typ

34: 44.4 2.8 3147 25 ABZ22451 Human MTP1 pro

35: 44.4 2.8 3147 25 ADD7180 Human membrane-Typ

36: 44.4 2.8 3147 25 ADD47181 Human membrane-Typ

37: 44.4 2.8 3147 25 ADD47225 Human membrane-Typ

38: 44.4 2.8 3149 21 AAA88493 Human matrixase c

39: 44.4 2.8 3152 22 AAH57431 Human intestine ca

40: 44.4 2.8 3159 21 AAA31657 Human peptidase H

41: 44.4 2.8 3413 23 AAC85629 DNA encoding novel

42: 42.2 2.6 971 22 AAC88893 Human tumour supr

43: 42.2 2.6 3780 22 AAC83823 DNA encoding human

44: 42.2 2.6 4174 22 AAC83821 DNA encoding human

45: 42.2 2.6 2900 22 AAH23602 Human SNC-19 codin

QY	181 AGCTCTCCACCCGGTGGAGCTGGGGGAGGGAGCTGCGGGACCAAGGGCTG 240	QY	1326 CCAGAGATAACCTCTCTCTGGACCCACCTTACACGGACCGAATCTG 1395
Db	241 CTATGTCATGATGTCGCTGCTGAAACAGGACTGTCACAGCTTACGGAGGGTG 300	Db	1234 CCAGAGATAACCTCTCTCTGGACCCACCTTACACGGACCGAATCTG 1293
QY	305 CGACGCTTCTCCAGTCGTCAGTCCCGGAGGGAGCTGCGGGACCAAGGGCTG 305	QY	1386 GTCCTGGGGGACCCCGGTTCTCTGAGCTACACTCTCTGGAGACGCCCT 1445
Db	301 CGGACGTTCTCCAGTCGTCAGTCCCGGAGGGAGCTGCGGGACCAAGGGCTG 360	Db	1294 GTCCTGGGGGACCCCGGTTCTCTGAGCTACACTCTCTGGAGACGCCCT 1353
QY	366 TTGAGATGGCTGGCGCCACCTGTCGTCACCTGAGCTGAGCTGAGCTG 425	QY	1446 GAGGGAGAGGGGGAGGAACTGAGATTGGGAGGGATGGGGGAGCTGGGG 1505
Db	361 TTGAGATGGCTGGCGCCACCTGTCGTCACCTGAGCTGAGCTGAGCTG 420	Db	1354 GAGGGAGAGGGGGAGGAACTGAGATTGGGAGGGATGGGGGAGCTGGGG 1413
QY	426 GCAAATGCCACGTCACCTGTCGTCACCTGAGCTGAGCTGAGCTG 485	QY	1506 GCTGAGGACCCGGAGCCGGACGGAGGGGGGGGGGGGGGGGGGGGGGGGG 1565
Db	421 GCAAATGCCACGTCACCTGTCGTCACCTGAGCTGAGCTGAGCTG 480	Db	1414 GCTGAGGAGCCGGAGGAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG 1473
QY	486 GCATTCGAGAGGG 545	QY	1566 TGA 1568
Db	481 GCATTGG 540	Db	1474 TGA 1476
QY	546 CCAGTCAGTCACTTCAGCAGCTGCGGGGGGGGGGGGGGGGGGGGGGGGG 605		
Db	541 CCAGTCAGTCACTTCAGCAGCTGCGGGGGGGGGGGGGGGGGGGGGGGGG 600		
QY	606 ATCTAACGTCAGTCACTTCAGCAGCTGCGGGGGGGGGGGGGGGGGGGGG 665		
Db	601 ATCTAACGTCAGTCACTTCAGCAGCTGCGGGGGGGGGGGGGGGGGGGGG 660		
QY	666 GAGGTCACAGAGGAGACTGGGGTTCTCTGGGCTGCGCCATGCGGACCTGCT 725		
Db	661 GAGGTCACAGAGGAGACTGGGGTTCTCTGGGCTGCGCCATGCGGACCTGCT 720		
QY	726 GTAATTGCGCCAGGGGGGTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 785		
Db	721 GTAATTGCGCCAGGGGGGTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 780		
QY	786 GCAAAATGCCACGGGCTGCACTTTCTGACACACACACACACACACAC 845		
Db	781 GCAAAATGCCACGGGCTGCACTTTCTGACACACACACACACACACAC 800		
QY	846 CCCAGAGACCAAGTCGATGACTTGTCTCTGTCCTCTGTCCTCTGTCCT 905		
Db	801 -----		
QY	906 GGGGTCAGCCGAGCCTCGAGTCAGGGCCAGGCCACACAGACAGATGAGAG 965		
Db	814 GGGGTCAGCCGAGCCTCGAGTCAGGGCCAGGCCACACAGACAGATGAGAG 873		
QY	966 GACCTTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1025		
Db	874 GACCTTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 933		
QY	1026 GACCTTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1085		
Db	934 GACCTTCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 993		
QY	1086 GAGGGTGG 1145		
Db	994 GAGGGTGG 1053		
QY	1146 TCTGCTTGGGATCTTCAGACGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1205		
Db	1054 TCTGCTTGGGATCTTCAGACGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1113		
QY	1206 GCTGGGTCCTCGTCGCTTGGGAGGGGGGGGGGGGGGGGGGGGGGGGGGG 1265		
Db	1114 GCTGGGTCCTCGTCGCTTGGGAGGGGGGGGGGGGGGGGGGGGGGGGGGG 1173		
QY	1266 CACCAAGAACTCTCCACCACTCTGATCTCCAGGACTCGGGTCTGAGAAGG 1325		
Db	1174 CACCAAGAACTCTCCACCACTCTGATCTCCAGGACTCGGGTCTGAGAAGG 1233		
		RESULT 4	
		AD50485	
		ID AD50485 Standard; cDNA; 1476 BP.	
		XX	
		AC AD50485;	
		XX	
		DT 24-MAR-2003 (first entry)	
		DE Human zcytor19 receptor variant cDNA.	
		XX	
		KW Human; Leukaemia; carcinoma; acquired immune deficiency syndrome; AIDS; melanoma; Kaposi's sarcoma; multiple myeloma; non-Hodgkin's lymphoma; hepatitis; infection; myocarditis; blood vessel formation; gene therapy; growth regulation; developmental process; immunotherapy; zcytor19; gene; receptor; variant; ss.	
		XX	
		OS Homo sapiens.	
		XX	
		FH	
		KEY	Location/Qualifiers
		FT	
		CDS	1..1476
		FT	
		FT	/*tag= a
		FT	/product= "Human zcytor19 receptor variant"
		FT	1..60
		FT	/*tag= b
		FT	61..1473
		FT	/*tag= c
		FT	/product= "Mature human zcytor19 receptor variant"
		XX	
		PN	WO200286087-A2.
		XX	
		PD	31-OCT-2002.
		PR	19-APR-2002; 2002WO-US12887.
		XX	
		PR	20-APR-2001; 2001US-285408P.
		PR	20-APR-2001; 2001US-285424P.
		PR	25-APR-2001; 2001US-286422P.
		PR	29-JUN-2001; 2001US-0895334.
		PR	22-OCT-2001; 2001US-341050P.
		PR	22-OCT-2001; 2001US-341105P.
		XX	
		XX	
		XX	(ZYMO) ZYMOGENETICS INC.
		PI	Sheppard PO, Fox BA, Klucher KM, Taft DW, Kindsvogel WR;
		XX	DR
		XX	WPI; 2003-093122/08.
		XX	P-PSB; AAB3276.
		PT	New zcyt020, zcyt021, zcyt022, zcyt024 and zcyt025 polypeptides and
		PT	polynucleotides useful for treating leukaemia, carcinoma, malignant
		PT	melanoma, AIDS-related Kaposi's sarcoma, myeloma, non-Hodgkin's

Qy 666 GAGGTCCAGAGGAGCTGG 686
 Db 709 GAGGTCCAGAGGAGCTGG 729

RESULT 9
 ABQ73079 ABQ73079 standard; cDNA; 673 BP.

XX AC ABQ73079;
 XX DT 25-SEP-2002 (first entry)

XX Human truncated soluble zcytor19 encoding cDNA SEQ ID NO:20.

XX Human; zcytor19; cytokine receptor; immunosuppressive; cytostatic; anti-rheumatic; antiarthritic; neuroprotective; antiinflammatory; antidiabetic; nephroprotective; dermatologic; anti-HIV; haemostatic; vaccine; immune system; T cell specific leukaemia; lymphoma; lupus; autoimmune disease; rheumatoid arthritis; multiple sclerosis; HIV; diabetes mellitus; inflammatory bowel disease; Crohn's disease; asthma; immunologic renal disease; glomerulonephritis; vasculitis; polyarteritis; mesangioproliferative disease; chronic lymphocytic leukaemia; bronchitis; secondary glomerulonephritis; scleroderma; amyloidosis; multiple myeloma; haemolytic uraemic syndrome; renal neoplasm; urological neoplasm; emphysema; chronic airway disease; chromosome 1; chromosome 1p36.11; gene; ss.

XX OS Homo sapiens.

XX Key Location/Qualifiers

PT CDS 1..636

PT /tag= a /product= "truncated soluble zcytor19"

PT 1..60

PT /tag= b /product= "truncated soluble zcytor19"

PT 61..633

PT /tag= c /product= "mature truncated soluble zcytor19"

PT

PN WO20024203-A2.

PD 06-JUN-2002.

XX 28-NOV-2001; 2001WO-US44808.

PR 28-NOV-2001; 2000US-253561P.

PR 07-FEB-2001; 2001US-267211P.

RA (ZYMO) ZYMOGENETICS INC.

XX Presnell SR, Xu W, Novak JE, Whitmore TE, Grant RJ;

XX DR WPI; 2002-527700/56.

XX DR P-PSDB; ABB8164.

XX Novel zcytor19 polypeptides and poly nucleotides useful for stimulating immune responses in animals for producing antibodies, and for treating autoimmune diseases, leukaemia and asthma -

XX PS Claim 2, Page 179-181; 2000pp; English.

XX The present invention describes an isolated human zcytor19 protein (1), and truncated zcytor19 proteins. (1) has immunosuppressive, cytostatic, anti-rheumatic, antiarthritic, neuroprotective, antiinflammatory, antidiabetic, nephroprotective, dermatological, anti-HIV and haemostatic activities, and can be used in vaccines. (1) or an antibody binding (1) can be used for suppressing the immune system for reducing rejection of tissue or organ transplants and grafts and for treating T-cell specific leukaemias or lymphomas and autoimmune diseases including rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel disease and Crohn's disease. The antibodies can also be used for treating immunologic renal diseases, glomerulonephritis, mesangioproliferative

CC disease, chronic lymphocytic leukaemia, secondary glomerulonephritis or vasculitis associated with lupus, polyarthritis, scleroderma, HIV related diseases, amyloidosis and haemolytic uraemic syndrome. (1) and the antibodies can also be used for renal or urological neoplasms and multiple myeloma. asthma, bronchitis, emphysema and other chronic airway diseases. Human zcytor19 is located to chromosome 1, more specifically to chromosome 1p36.11. The present sequence encodes a human truncated soluble zcytor19 protein from the present invention.

XX SQ Sequence 673 BP; 127 A; 223 C; 182 G; 141 T; 0 other;

Query Match Best Local Similarity 31.1%; Score 498; DB 24; Length 673; Matches 509; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

Db 7 ATGGCGGCCGAGGCTGGAGGCCCTGCTCTGCTGCTGAGGCGGCCGAGG 66

Db 1 ATGGGGGAGCCGAGGCTGGGCCCTGCTCTGCTGCTGAGGCGGCCGAGG 60

Qy 67 AGSCCCCTCTGACCCCTCCGAGATGAGTGAAGTGTCTCCAGAACCTACCGCTPAC 126

Db 61 AGGCCCGCTCTGACCCCTCCGAGATGAGTGAAGTGTCTCCAGAACCTACCGCTPAC 120

Qy 127 CTGACATGCTGCCAGGCTGGACACCCAGGATGAGCTGCTGCTTATTTGSCC-ATCG 185

Db 121 CTGACATGCTGCCAGGCTGGACACCCAGGATGAGCTTGTGCTATTCAG 180

Qy 186 AGCTCTCCACCCGAGAGCTGGAGGAGAGTGGAGAGTGGAGGAGACAGAGCTG 245

Db 181 AGCTCTCCACCCGAGAGCTGGAGGAGAGTGGAGGAGACAGAGCTG 240

Qy 246 CTATGCTTGTATGATGAGCTGAGAACAGACCTACAGTCAAGTCTGAGGACGGCTG 305

Db 241 CTATGCTTGTATGATGAGCTGAGAACAGACCTACAGTCAAGTCTGAGGACGGCTG 300

Db 306 CGGACGAGTTCTCCGAGCTCAAGTCCCCTGGAGCTGGCTGAGTGGATTACCT 365

Db 301 CGGACGAGTTCTCCGAGCTCAAGTCCCCTGGAGCTGGCTGAGTGGATTACCT 360

Qy 336 TTGGAGTGGACCCGACCTGCTGGCTGCTGAGCTACCTACAGTCAAGTCTGAGGACGGCTG 425

Db 361 TTGGAGTGGACCCGACCTGCTGGCTGCTGAGCTACCTACAGTCAAGTCTGAGGACGGCTG 420

Qy 426 GCGCATGCGCACTACCGCTGGCCGCCCTGCTATGCCCTGGATGAGTGGATGAGGTG 485

Db 421 GCGCATGCGCACTACCGCTGGCCGCCCTGCTATGCCCTGGATGAGTGGATGAGGTG 480

Qy 486 GCATTCTGAGGAGGGGGCGGAAACAG 515

Db 481 GCATTCTGAGGAGGGGGCGGAAACAG 510

RESULT 10

XX AD50488 standard; cDNA; 674 BP.

XX AAD50488

XX AC AAD50488;

XX DT 24-MAR-2003 (first entry)

XX Human zcytor19 truncated soluble receptor cDNA.

XX DB Human zcytor19 truncated soluble receptor cDNA.

XX Human; leukaemia, carcinoma, acquired immune deficiency syndrome, AIDS, melanoma, Kaposi's sarcoma; multiple myeloma, non-Hodgkin's lymphoma, hepatitis; infection; mycosis; blood vessel formation; immunotherapy; gene therapy; growth regulation; developmental process; immunotherapy; zcytor19; gene; receptor; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

PT CDS 1..636

PT /tag= a

FT FT sig_peptide /product= "Human zcytor19 truncated soluble receptor" 1..50
FT FT mat_peptide /"tag" b 61..33
FT FT /"tag" c /product= "Mature human zcytor19 truncated soluble receptor" 1..50
FT FT XX PN WO20286087-A2.
XX XX XX PD 31-OCT-2002.
XX XX PR 19-APR-2002; 2002WO-US12887.
XX XX PR 20-APR-2001; 2001US-285408P.
XX XX PR 20-APR-2001; 2001US-285424P.
XX XX PR 25-APR-2001; 2001US-086492P.
XX XX PR 29-JUN-2001; 2001US-0895834.
XX XX PR 22-OCT-2001; 2001US-341050P.
XX XX PR 22-OCT-2001; 2001US-341105P.
XX XX PA (ZYMO) ZYMOGENETICS INC.
XX XX PI Sheppard PO, FOX BA, Klucher KM, Taft DW, Kindsbogel WR;
XX XX DR WPI, 2003-093122/08.
DR DR P-PSB, AAE32768.
XX XX PR New zcyt020, zcyt021, zcyt022, zcyt024 and zcyt025, polypeptides and
PR PR poly nucleotides useful for treating leukemia, carcinoma, malignant
PT PT melanoma, AIDS-related Kaposi's sarcoma, myeloma, non-Hodgkin's
XX XX lymphoma, hepatitis and infections -
XX XX PS Example 30; Page 147-148; 160pp; English.
XX XX CC The invention relates to zcyt020, zcyt021, zcyt022, zcyt024 and zcyt025
CC CC polypeptides and poly nucleotides. Sequences of the invention are useful
CC CC for treating hairy cell leukemia, renal cell or basal cell carcinoma,
CC CC malignant melanoma, AIDS-related Kaposi's sarcoma, multiple myeloma,
CC CC non-Hodgkin's lymphoma, hepatitis B, C or D, infections (e.g. bacterial,
CC CC fungal or protozoal) or myocarditis. The invention is useful for growth
CC CC regulation in the liver, blood vessel formation and other developmental
CC CC processes. The invention is also useful in immunotherapy and gene
CC CC therapy. The present sequence is human zcyt019 truncated soluble
CC CC receptor cDNA.
XX XX SQ sequence 674 BP; 128 A; 223 C; 182 G; 141 T; 0 other;
QY Query Match 31.1%; Score 499; DB 25; Length 674;
QY Best Local Similarity 99.8%; Pred. No. 5; Be-19%;
Matches 509; Conservative 0; Mismatches 1; Indels 1; Gaps 1; Gaps 1.
QY 7 ATGGGGGGCCGAGCCCTGGAGCCCTGGCTGGCCCTCTGAGCCCTGGAGGG 66
Db 1 ATGGGGGGCCGAGCCCTGGAGCCCTGGCTGGCCCTCTGAGCCCTGGAGGG 66
QY 67 AGGCCCGCTGCCCCCTCCAGATGAGCTGACCTGCTCCAGACTCAGGTTCA 126
Db 61 AGGCCCGCTGCCCCCTCCAGATGAGCTGACCTGCTCCAGACTCAGGTTCA 120
QY 127 CTGAGATGCTCCAGAGCTTGAGCCAGATGACCTATTTGGCC-ATCAG 185
Db 121 CTGAGATGCTCCAGAGCTTGAGCCAGATGACCTATTTGGCTATCAG 180
QY 186 AGCTTCCACCGTAGACCTGGGGGGAGTGGAGAGGTGGGGAGAACGAGGT 245
Db 181 AGCTTCCACCGTAGACCTGGGGGGAGTGGAGAGGTGGGGAGAACGAGGT 240
QY 246 CTATGTCATGAGTCCTGAGAGAACGAGACTGACACAGTCAAGGGAGGGT 305
Db 241 CTATGTCATGAGTCCTGAGAGAACGAGACTGACACAGTCAAGGGAGGGT 300
QY 306 CGGAGCGTTCTCCACGCTCCAGAGCCCTGGGGAGTGGCTCGAACTGGATTACCT 365

CC of the polynucleotides. The probes can be used for chromosome mapping of the polynucleotide and for detection of transcription levels. Ribozymes or antisense oligonucleotides can be generated. The polynucleotides and their gene products are used as genetic or biochemical markers (e.g. in blood or tissue) that will detect the earliest changes along the carcinogenesis pathway and/or monitor the efficacy of therapies and preventive interventions. The polynucleotides, polypeptides and antibodies against them can be used in pharmaceutical compositions to treat the cancers and proliferative disorders such as neoplasia, dysplasia and hyperplasia.

XX Sequence 392 BP; 76 A; 78 C; 132 G; 106 T; 0 other;

Query Match 10.3%; Score 165; DB 22; Length 392;
Best Local Similarity 97.1%; Pred. No. 9; 1e-33; Matches 168; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
Db 510 AACAGAGCCATTTCAGCTCACTTCCCAGCCATGCCAGGCCA 569
207 AACAGAGCCATTTCAGCTCACTTCCCAGCCATGCCAGGCCA 148
QY 570 GCTGCCAGGACACCATGCTCACTGCCAGCCATGCCAGGCCA 629
147 GCTGCCAGGACACCATGCTCACTGCCAGCCATGCCAGGCCA 88
Db 630 TACAGCAAGTCTTACGCCACCTCTCTGCTGAGGTCGCCAGAGCGAA 682
87 TACAGCAAGTCTTACGCCACCTCTCTGCTGAGGTCGCCAGAGCGAA 35
RESULT 15

XX ID AAF65522 Standard; cDNA; 382 BP.

XX AC AAF65522;

XX DT 09-APR-2001 (first entry)

DB Novel human polynucleotide, SEQ ID NO: 1278.

XX KW Human; cytostatic; gene therapy; colon cancer; prostate cancer; breast cancer; lung cancer; cancer detection; ss.

XX OS Homo sapiens.

XX PN WO200102568-A2

XX PD 11-JAN-2001.

XX PP 30-JUN-2000; 2000000-US18374.

XX PR 02-JUL-1999; 99US-0142310.

XX PR 02-JUL-1999; 99US-0142311.

XX PA (CHIR) CHIRON CORP.

XX (HYSE-) HYSEQ INC.

XX PT Williams LT, Escobedo J, Innis MA, Garcia PD, Klinger J, Kassam A, Reinhard C, Ranazzo F, Kennedy GC, Pot D, Lamont G, Brmanac R, Crkvenjakov R, Dumanac S, Dickson M, Labat I, Leshkowitz D, Kita D, Garcia V, Jones LW, Strache-Crain B, DR WPI; 2001-091805/10.

XX PT Library of polynucleotides for diagnosing a cancerous state of a mammalian cell and detecting cancer, particularly of the colon or prostate, comprises 3351 human polynucleotide sequences -

XX Claim 9; Page 727; 1046pp, English.

CC The present sequence is one of 3351 sequences in a library of human polynucleotides. The library is used to detect differentially expressed genes correlated with a cancerous state of a mammalian cell and can

CC detect colon, prostate, breast and lung cancer. The library can be used to produce probes for detection of mRNA and to produce additional copies of the polynucleotides. The probes can be used for chromosome mapping of the polynucleotide and for detection of transcription levels. Ribozymes or antisense oligonucleotides can be generated. The polynucleotides and their gene product are used as genetic or biochemical markers (e.g. in blood or tissue) that will detect the earliest changes along the carcinogenesis pathway and/or monitor the efficacy of therapies and preventive interventions. The polynucleotides, polypeptides and antibodies against them can be used in pharmaceutical compositions to treat the cancers and proliferative disorders such as neoplasia, dysplasia and hyperplasia.

XX Sequence 382 BP; 77 A; 77 C; 130 G; 98 T; 0 other;

Query Match 10.2%; Score 163.4; DB 22; Length 382;
Best Local Similarity 96.5%; Pred. No. 2.3e-32; Matches 157; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
Db 510 AACAGAGCCATTTCAGCTCACTTCCCAGCCATGCCAGGCCA 569
207 AACAGAGCCATTTCAGCTCACTTCCCAGCCATGCCAGGCCA 148
QY 570 GCTGCCAGGAAACCATGCTCACTGCCAGCCATGCCAGGCCA 629
147 GCTGCCAGGAAACCATGCTCACTGCCAGCCATGCCAGGCCA 88
Db 630 TACAGCAAGTCTTACGCCACCTCTCTGCTGAGGTCGCCAGAGCGAA 682
87 TACAGCAAGTCTTACGCCACCTCTCTGCTGAGGTCGCCAGAGCGAA 35
RESULT 15

XX ID AAF65522 Standard; cDNA; 382 BP.

XX AC AAF65522;

XX DT 09-APR-2001 (first entry)

DB Novel human polynucleotide, SEQ ID NO: 1278.

XX KW Human; cytostatic; gene therapy; colon cancer; prostate cancer; breast cancer; lung cancer; cancer detection; ss.

XX OS Homo sapiens.

XX PN WO200102568-A2

XX PD 11-JAN-2001.

XX PP 30-JUN-2000; 2000000-US18374.

XX PR 02-JUL-1999; 99US-0142310.

XX PR 02-JUL-1999; 99US-0142311.

XX PA (CHIR) CHIRON CORP.

XX (HYSE-) HYSEQ INC.

XX PT Williams LT, Escobedo J, Innis MA, Garcia PD, Klinger J, Kassam A, Reinhard C, Ranazzo F, Kennedy GC, Pot D, Lamont G, Brmanac R, Crkvenjakov R, Dumanac S, Dickson M, Labat I, Leshkowitz D, Kita D, Garcia V, Jones LW, Strache-Crain B, DR WPI; 2001-091805/10.

XX PT Library of polynucleotides for diagnosing a cancerous state of a mammalian cell and detecting cancer, particularly of the colon or prostate, comprises 3351 human polynucleotide sequences -

XX Claim 9; Page 727; 1046pp, English.

CC The present sequence is one of 3351 sequences in a library of human polynucleotides. The library is used to detect differentially expressed genes correlated with a cancerous state of a mammalian cell and can